Farxiga Tablet, Film Coated
Product Images NDC 70518-4614

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Farxiga (NDC 70518-4614). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Mm1 (Farxiga 5mg 70518 4614 00)

Mm1 (Farxiga 5mg 70518 4614 00)
This is a description of Fal’Xlga Tablet manufactured by AstraZeneca. The tablets contain dapagliflozin 5mg and come in a box of 50 tablets. The usual dosage information can be found in the insert. It is important to store the medication at room temperature and keep it out of reach of children. The medication is repackaged by RemedyRepack in Indiana, PA.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
This is prescription information for a medication called Fal’Xlga Tablet, containing dapagliflozin 19850. The manufacturer is AstraZeneca. The usual dosage information can be found in the insert provided with the medication. It is recommended to keep the medication out of reach of children and store it at 20-25°C. It is a yellow, round tablet. The medication has been repackaged by RemedyRepack Inc. in Indiana, PA. Contact information for RemedyRepack is also provided.*
FDA Label Image

Dapagliflozin Chemical Structure (Dapagliflozin Struct)

Dapagliflozin Chemical Structure (Dapagliflozin Struct)
FDA Label Image

Figure 1 (Farxiga Fig1)

Figure 1 (Farxiga Fig1)
The text provides information about 24-hour urinary glucose levels measured in healthy subjects and subjects with T20M. It also includes data related to Dapagliflozin dose in milligrams and fitted lines for healthy subjects and those with T20M.*
FDA Label Image

Figure_11 (Figure 11)

Figure_11 (Figure 11)
This text appears to provide data from different studies on the LVEF (%) category in heart failure patients treated with FARXIGA. The studies mentioned are DAPA-HF and DELIVER. It includes information on the number of patients in each group, the hazard ratio (HR) for FARXIGA versus Placebo, and confidence intervals. The results suggest that FARXIGA shows better outcomes compared to Placebo in terms of LVEF (%) category based on the provided HR values.*
FDA Label Image

Figure-8a (Figure 8a)

Figure-8a (Figure 8a)
This text provides information about the percentage of patients experiencing an event while taking FARXIGA compared to a placebo. It includes a graph displaying the number of patients at risk over a period of 36 months from randomization. The results show that FARXIGA had a hazard ratio of 0.82 (95% CI: 0.69, 0.98) with a p-value of 0.0294 compared to the placebo group.*
FDA Label Image

Figure 10a (Figure 10a)

Figure 10a (Figure 10a)
This is a list of characteristics and results related to a study, including demographics like age and race, health conditions like diabetes and atrial fibrillation, and measurements such as BMI and eGFR. It also shows comparisons between different groups for the primary endpoint composite. The study involves the drug FARXIGA and a placebo, with outcomes presented as TR (95% CI) values.*
FDA Label Image

Figure-10b (Figure 10b)

Figure-10b (Figure 10b)
The text provides the characteristics of a study population, including factors such as age, sex, race, geographic region, comorbidities like diabetes and atrial fibrillation, and baseline measurements like BMI, eGFR, and blood pressure. It also mentions the comparison between two groups (FARXIGA and Placebo) for various endpoints like HR with 95% CI. This information seems to be from a clinical trial analyzing the effects of FARXIGA compared to a Placebo on a primary endpoint.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
This text provides a statistical overview of patients in a clinical trial with Farxiga and Placebo treatment. It shows the number of patients at risk over different time intervals (6, 12, 24, 30, 36, 48, and 60 months). The numbers indicate the progression of patients over time for both Farxiga and Placebo groups. The data suggests a comparison between the two treatments in terms of patient outcomes and event occurrence.*
FDA Label Image

Figure_6 (Figure 6)

Figure_6 (Figure 6)
This data shows the comparison between FARXIGA and Placebo in terms of event occurrence in patients. FARXIGA displayed a significantly lower risk of the event compared to Placebo, with a hazard ratio of 0.61 (95% CI: 0.51, 0.72) and a P-value of <0.0001. The study period ranged from 4 to 32 months, involving 2152 patients for both FARXIGA and Placebo.*
FDA Label Image

Figure-7a (Figure 7a)

Figure-7a (Figure 7a)
This is a description of a clinical trial comparing the drug FARXIGA to a placebo over a period of time in months. It provides hazard ratio (HR), confidence intervals (CI), P-value, and a graph showing the number of patients at risk over the study period. The results indicate a statistically significant difference between FARXIGA and the placebo.*
FDA Label Image

Figure_7b (Figure 7b)

Figure_7b (Figure 7b)
This data table presents information on the percentage of patients experiencing an event in a clinical trial comparing the drug FARXIGA with a placebo. The table includes the number of patients at risk at different time points (in months) from randomization, and provides hazard ratio (HR) with 95% confidence interval (CI) and corresponding p-values for the comparison between FARXIGA and Placebo.*
FDA Label Image

Figure-8b (Figure 8b)

Figure-8b (Figure 8b)
This is a comparison of the number of patients experiencing an event in a clinical trial between the medication FARXIGA and a placebo. The hazard ratio (HR) with a corresponding 95% confidence interval (CI) is 0.88 (0.74, 1.05) for FARXIGA compared to placebo. The table also shows the number of patients at risk over different time points in months from randomization, ranging from 15 to 36 months.*
FDA Label Image

Figure-9a (Figure 9a)

Figure-9a (Figure 9a)
FDA Label Image

Figure-9b (Figure 9b)

Figure-9b (Figure 9b)
This is a study comparing the drug FARXIGA with a placebo over a period of 36 months. The survival rate curve for the patients is displayed with time points labeled on the x-axis. The text includes the number of patients at risk for FARXIGA and placebo at different time points during the study. The hazard ratio (HR) with a 95% confidence interval (CI) is also provided.*
FDA Label Image

Figure-2 (Firgure 2)

Figure-2 (Firgure 2)
FDA Label Image

Figure-3 (Firgure 3)

Figure-3 (Firgure 3)
FDA Label Image

Figure 5 (Firgure 5)

Figure 5 (Firgure 5)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.